An Expert Overview on Therapies in Non-Transfusion-Dependent Thalassemia: Classical to Cutting Edge in Treatment

References

• Weatherall DJ. The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Rev. 2012;26:S3–S6.
   PubMed Web of Science ®Google Scholar
• Taher A, Isma’eel H, Cappellini MD. Thalassemia intermedia: revisited. Blood Cells Mol Dis. 2006;37(1):12–20.
   PubMed Web of Science ®Google Scholar
• Camaschella C, Cappellini MD. Thalassemia intermedia. Haematologica. 1995;80(1):58–68.
   PubMed Web of Science ®Google Scholar
• Galanello R, Cao A. Relationship between genotype and phenotype: thalassemia intermedia. Ann N Y Acad Sci. 1998;850(1):325–333.
   PubMedGoogle Scholar
• Steinberg MH, Forget BG, Higgs DR, Weatherall DJ, editors. Disorders of Hemoglobin Genetics. Pathophysiol Clin Manage. Cambridge: Cambridge University Press; 2009.
   Google Scholar
• Sturgeon P, Itano HA, Bergren W. Genetic and biochemical studies of ‘intermediate’ types of Cooley’s anaemia. Br J Haematol. 1955;1(3):264–277.
   PubMed Web of Science ®Google Scholar
• Christianson A, Howson CP, Modell B, editors. March of dimes: Global report on birth defects, the hidden toll of dying and disabled children. White Plains (NY): March of Dimes Birth Defects Foundation; 2006.
   Google Scholar
• Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood. 2010;115(22):4331–4336.
   PubMed Web of Science ®Google Scholar
• Weatherall DJ, Clegg JB. The Thalassaemia Syndromes. 4th ed. Oxford (Oxon, UK): Blackwell Scientific; 2001.
   Google Scholar
• Thein SL. Genetic insights into the clinical diversity of beta thalassaemia. Br J Haematol. 2004;124(3):264–274.
   PubMed Web of Science ®Google Scholar
• Weatherall D. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat Rev Genet. 2001;2(4):245–255.
   PubMed Web of Science ®Google Scholar
• Pooladi A, Gheshlagh RG, Kahrizi N. The spectrum of alpha and beta thalassemia mutations: a 10-year population-based study of the Premarital Health Screening Program in West of Iran. Iran J Ped Hematol Oncol. 2022;12(3):190–198.
   Web of Science ®Google Scholar
• Cao A, Galanello R. Beta-thalassemia. Genet Med. 2010;12(2):61–76.
   PubMed Web of Science ®Google Scholar
• Forget BG. Molecular basis of hereditary persistence of fetal hemoglobin. Ann N Y Acad Sci. 1998;850:38–44.
   PubMed Web of Science ®Google Scholar
• Fucharoen S, Pengjam Y, Surapot S, et al. Molecular characterization of (deltabeta)(0)/beta(0)-thalassemia and (deltabeta)(0)-thalassemia/hemoglobin E in Thai patients. Eur J Haematol. 2001;67(4):258–262.
   PubMed Web of Science ®Google Scholar
• Pandey H, Ranjan R, Singh K, et al. Contrasting co-inheritance of alpha and beta mutations in delta beta thalassemia and hereditary persistence of fetal hemoglobin: a study from India. Hematology. 2018;23(9):692–696.
   PubMed Web of Science ®Google Scholar
• Verma S, Bhargava M, Mittal S, et al. Homozygous delta-beta thalassemia in a child: a rare cause of elevated fetal hemoglobin. Iran J Ped Hematol Oncol. 2013;3(1):222–227.
   PubMedGoogle Scholar
• Rahimi Z, Akramipour R, Korani S, et al. Hb D-Punjab [beta 121 (GH4) Glu–>Gln]/beta0-thalassemia [IVSII.1(G–>A)] in two cases from an Iranian family: first report. Am J Hematol. 2006;81(4):302–303.
   PubMed Web of Science ®Google Scholar
• Tsistrakis G, Scampardonis G, Clonizakis J, et al. Haemoglobin D and D Thalassaemia. Acta Haematol. 1975;54(3):172–179.
   PubMed Web of Science ®Google Scholar
• Weatherall DJ, Clegg JB, editors. Management and prognosis in the thalassaemia syndromes. The Thalassaemia Syndromes. 4th ed. Oxford: Blackwell Scientific; 2001. p. 630–685.
   Google Scholar
• Pandey S, Mishra RM, Pandey S, et al. Molecular characterization of hemoglobin D Punjab traits and clinical-hematological profile of the patients. Sao Paulo Med J. 2012;130(4):248–251.
   PubMed Web of Science ®Google Scholar
• Thein SL. The molecular basis of β-thalassemia. Cold Spring Harb Perspect Med. 2013;3(5):a011700.
   PubMed Web of Science ®Google Scholar
• Huisman TJH. Silent β-thalassemia and thalassemia intermedia. Haematologica. 1990;75(Suppl 5):1–8.
   PubMed Web of Science ®Google Scholar
• Viprakasit V, Tyan P, Rodmai S, et al. Identification and key management of non-transfusion-dependent thalassaemia patients: not a rare but potentially under-recognised condition. Orphanet J. Rare Dis. 2014;9:131.
   PubMed Web of Science ®Google Scholar
• Borgna Pignatti C, Marsella M, Zanforlin N. The natural history of thalassemia intermedia. Ann N Y Acad Sci. 2010;1202(1):214–220.
   PubMedGoogle Scholar
• Musallam KM, Rivella S, Vichinsky E, et al. Non-transfusion-dependent thalassemias. Haematologica. 2013;98(6):833–844.
   PubMed Web of Science ®Google Scholar
• Camaschella C, Kattamis A, Petroni D, et al. Different hematological phenotypes caused by the interaction of triplicated alpha globin genes and heterozygous β thalassemia. Am J Hematol. 1997;55(2):83–88.
   PubMed Web of Science ®Google Scholar
• Taher AT, Radwan A, Viprakasit V. When to consider transfusion therapy for patients with non transfusion dependent thalassaemia. Vox Sang. 2015;108(1):1–10.
   PubMed Web of Science ®Google Scholar
• Haidar R, Mhaidli H, Taher AT. Paraspinal extramedullary hematopoiesis in patients with thalassemia intermedia. Eur Spine J. 2010;19(6):871–878.
   PubMed Web of Science ®Google Scholar
• Karimi M, Cohan N, De Sanctis V, et al. Guidelines for diagnosis and management of beta-thalassemia intermedia. Pediatr Hematol Oncol. 2014;31(7):583–596.
   PubMed Web of Science ®Google Scholar
• Auer JW, Berent R, Weber T, et al. Iron metabolism and development of atherosclerosis. Circulation. 2002;106(2):e7.
   PubMed Web of Science ®Google Scholar
• Balla J, Vercellotti GM, Nath K, et al. Haem, haem oxygenase and ferritin in vascular endothelial cell injury. Nephrol Dial Transplant. 2003;18(suppl 5):v8–v12.
   PubMed Web of Science ®Google Scholar
• Borgna Pignatti C, Vergine G, Lombardo T, et al. Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol. 2004;124(1):114–117.
   PubMed Web of Science ®Google Scholar
• Huang Y, Lei Y, Liu R, et al. Imbalance of erythropoiesis and iron metabolism in patients with thalassemia. Int J Med Sci. 2019;16(2):302–310.
   PubMed Web of Science ®Google Scholar
• Mariani R, Trombini P, Pozzi M, et al. Iron metabolism in thalassemia and sickle cell disease. Mediterr J Hematol Infect Dis. 2009;1(1):e2009006.
   PubMedGoogle Scholar
• Musallam KM, Cappellini MD, Wood JC, et al. Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia. Haematologica. 2011;96(11):1605–1612.
   PubMed Web of Science ®Google Scholar
• Taher A, El Rassi F, Isma’eel H, et al. Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. Haematologica. 2008;93(10):1584–1586.
   PubMed Web of Science ®Google Scholar
• Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007;13(9):1096–1101.
   PubMed Web of Science ®Google Scholar
• Weizer Stern O, Adamsky K, Amariglio N, et al. mRNA expression of iron regulatory genes in beta thalassemia intermedia and beta thalassemia major mouse models. Am J Hematol. 2006;81(7):479–483.
   PubMed Web of Science ®Google Scholar
• Asadov C, Alimirzoeva Z, Mammadova T, et al. β-Thalassemia intermedia: a comprehensive overview and novel approaches. Int J Hematol. 2018;108(1):5–21.
   PubMed Web of Science ®Google Scholar
• Musallam KM, Cappellini MD, Wood JC, et al. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood Rev. 2012;26(Suppl 1):S16–S19.
   PubMed Web of Science ®Google Scholar
• Vichinsky EP, MacKlin EA, Waye JS, et al. Changes in the epidemiology of thalassemia in North America: a new minority disease. Pediatrics. 2005;116(6):e818–e825.
   PubMed Web of Science ®Google Scholar
• Taher A, Vichinsky E, Musallam K, et al. editors. Guidelines for the management of Non Transfusion Dependent Thalassaemia (NTDT). Nicosia (Cyprus): Thalassaemia International Federation; 2013.
   Google Scholar
• Tai SM, Chan JSH, Ha SY, et al. Successful treatment of spinal cord compression secondary to extramedullary hematopoietic mass by hypertransfusion in a patient with thalassemia major. Pediatr Hematol Oncol. 2006;23(4):317–321.
   PubMed Web of Science ®Google Scholar
• Tan T-C, Tsao J, Cheung F-C. Extramedullary haemopoiesis in thalassemia intermedia presenting as paraplegia. J Clin Neurosci. 2002;9(6):721–725.
   PubMed Web of Science ®Google Scholar
• Tsitouridis J, Stamos S, Hassapopoulou E, et al. Extramedullary paraspinal hematopoiesis in thalassemia: CT and MRI evaluation. Eur J Radiol. 1999;30(1):33–38.
   PubMed Web of Science ®Google Scholar
• Karimi M, Cohan N, Pishdad P. Hydroxyurea as a first-line treatment of extramedullary hematopoiesis in patients with beta thalassemia: four case reports. Hematology. 2015;20(1):53–57.
   PubMed Web of Science ®Google Scholar
• Weatherall D, Clegg JB. Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ. 2001;79(8):704–712.
   PubMed Web of Science ®Google Scholar
• Nienhuis AW. Summary and perspective. [Abstract] Weatherall DJ, Braaten D, editors Presented at the Ninth Cooley’s Anemia Symposium, held at Manhattan, NY, USA, October 21–24, 2009. Ann N Y Acad Sci. 2010;1202(1):248–254.
   PubMedGoogle Scholar
• Vichinsky EP, Neufeld EJ. Preface to Cooley’s Anemia: Ninth Symposium. In: Weatherall DJ, Braaten D, editors. Presented at the Ninth Cooley’s Anemia Symposium, Manhattan, NY, USA, 2010. p. ix–x.
   Google Scholar
• Saeidnia M, Nowrouzi-Sohrabi P, Erfani M, et al. The effect of curcumin on serum copper, zinc, and zinc/copper ratio in patients with β-thalassemia intermedia: a randomized double-blind clinical trial. Ann Hematol. 2021;100(3):627–633.
   PubMed Web of Science ®Google Scholar
• Jiao Y, Wilkinson IJ, Pietsch EC, et al. Iron chelation in the biological activity of curcumin. Free Radic Biol Med. 2006;40(7):1152–1160.
   PubMed Web of Science ®Google Scholar
• Alok A, Singh ID, Singh S, et al. Curcumin–pharmacological actions and its role in oral submucous fibrosis: a review. J Clin Diagn Res. 2015;9(10):ZE01–ZE03.
   PubMedGoogle Scholar
• Saeidnia M, Fazeli P, Erfani M, et al. The effect of curcumin on iron overload in patients with beta-thalassemia intermedia. Clin Lab. 2022;68(3) 545–550:545–550.
   Web of Science ®Google Scholar
• Ahmad Fuzi SF, Koller D, Bruggraber S, et al. A 1-h time interval between a meal containing iron and consumption of tea attenuates the inhibitory effects on iron absorption: a controlled trial in a cohort of healthy UK women using a stable iron isotope. Am J Clin Nutr. 2017;106(6):1413–1421.
   PubMed Web of Science ®Google Scholar
• Rund D, Rachmilewitz E. New trends in the treatment of beta-thalassemia. Crit Rev Oncol Hematol. 2000;33(2):105–118.
   PubMed Web of Science ®Google Scholar
• Grinberg LN, Newmark H, Kitrossky N, et al. Protective effects of tea polyphenols against oxidative damage to red blood cells. Biochem Pharmacol. 1997;54(9):973–978.
   PubMed Web of Science ®Google Scholar
• Karimi M, Zarei T, Bahmanimehr A, et al. Long-term safety and efficacy of hydroxyurea in patients with non-transfusion-dependent β-thalassemia: a comprehensive single-center experience. Ann Hematol. 2021;100(12):2901–2907.
   PubMed Web of Science ®Google Scholar
• Yasara N, Premawardhena A, Mettananda S. A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemic. Orphanet J Rare Dis. 2021;16(1):114.
   PubMed Web of Science ®Google Scholar
• Foong WC, Ho JJ, Loh CK, et al. Hydroxyurea for reducing blood transfusion in non transfusion dependent beta thalassaemias. Cochrane Database Syst Rev. 2016;10(10):CD011579.
   PubMedGoogle Scholar
• Algiraigri AH, Wright NA, Paolucci EO, et al. Hydroxyurea for nontransfusion-dependent β-thalassemia: a systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2017;10(3):116–125.
   PubMedGoogle Scholar
• Taher AT, Musallam KM, Karimi M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood. 2010;115(10):1886–1892.
   PubMed Web of Science ®Google Scholar
• Haghpanah S, Karimi M. Cerebral thrombosis in patients with β-thalassemia: a systematic review. Blood Coagul Fibrinolysis. 2012;23(3):212–217.
   PubMed Web of Science ®Google Scholar
• Karimi M, Haghpanah S, Pishdad P, et al. Frequency of silent brain lesions and aspirin protection evaluation over 3 years follow-up in beta thalassemia patients. Ann Hematol. 2019;98(10):2267–2271.
   PubMed Web of Science ®Google Scholar
• Musallam KM, Taher AT, Karimi M, et al. Cerebral infarction in β-thalassemia intermedia: breaking the silence. Thromb Res. 2012;130(5):695–702.
   PubMed Web of Science ®Google Scholar
• Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med. 1999;341(19):1447–1457.
   PubMed Web of Science ®Google Scholar
• Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331(9):567–573.
   PubMed Web of Science ®Google Scholar
• Olivieri NF. The beta-thalassemias. N Engl J Med. 1999;341(2):99–109.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331(9):574–578.
   PubMed Web of Science ®Google Scholar
• Aessopos A, Farmakis D, Deftereos S, et al. Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest. 2005;127(5):1523–1530.
   PubMed Web of Science ®Google Scholar
• Aessopos A, Farmakis D, Karagiorga M, et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood. 2001;97(11):3411–3416.
   PubMed Web of Science ®Google Scholar
• Moghaddam HM, Badiei Z, Eftekhari K, et al. Prevalence of pulmonary hypertension in patients with thalassemia intermedia in 2009: a single center’s experience. Electron Physician. 2015;7(3):1102–1107.
   PubMedGoogle Scholar
• Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D34–D41.
   PubMed Web of Science ®Google Scholar
• Ussavarungsi K, Burger CD. Pulmonary arterial hypertension in a patient with β-thalassemia intermedia and reversal with infusion epoprostenol then transition to oral calcium channel blocker therapy: review of literature. Pulm Circ. 2014;4(3):520–526.
   PubMed Web of Science ®Google Scholar
• Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327(2):76–81.
   PubMed Web of Science ®Google Scholar
• Sadaf A, Hasan B, Das JK, et al. Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia. Cochrane Database Syst Rev. 2018;7(7):CD011626.
   PubMedGoogle Scholar
• Higgs DJ. The thalassaemia syndromes. Q J Med. 1993;86(9):559–564.
   PubMedGoogle Scholar
• Vichinsky E, Neumayr L, Trimble S, CDC Thalassemia Investigators, et al. Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME). Transfusion. 2014;54(4):972–81; quiz 971.
   PubMed Web of Science ®Google Scholar
• Spanos T, Karageorga M, Ladis V, et al. Red cell alloantibodies in patients with thalassemia. Vox Sang. 1990;58(1):50–55.
   PubMed Web of Science ®Google Scholar
• Al-Riyami AZ, Daar S. Red cell alloimmunization in transfusion-dependent and transfusion-independent beta thalassemia: a review from the Eastern Mediterranean Region (EMRO). Transfus Apher Sci. 2019;58(6):102678.
   PubMed Web of Science ®Google Scholar
• Ang AL, Lim CY, Ng WY, et al. Non transfusion dependent thalassemia is independently associated with higher alloimmunization risk than transfusion dependent thalassemia and would benefit the most from extended red cell antigen matching. Transfusion. 2021;61(9):2566–2577.
   PubMed Web of Science ®Google Scholar
• Blumberg N, Heal JM, Gettings KF. WBC reduction of RBC transfusions is associated with a decreased incidence of RBC alloimmunization. Transfusion. 2003;43(7):945–952.
   PubMed Web of Science ®Google Scholar
• Singer ST, Wu V, Mignacca R, et al. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. Blood. 2000;96(10):3369–3373.
   PubMed Web of Science ®Google Scholar
• Gaziev J, Lucarelli G. Stem cell transplantation for hemoglobinopathies. Curr Opin Pediatr. 2003;15(1):24–31.
   PubMed Web of Science ®Google Scholar
• Lucarelli G, Isgrò A, Sodani P, et al. Hematopoietic stem cell transplantation in thalassemia and sickle cell anemia. Cold Spring Harb Perspect Med. 2012;2(5):a011825.
   PubMed Web of Science ®Google Scholar
• Baronciani D, Angelucci E, Potschger U, et al. Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000-2010. Bone Marrow Transplant. 2016;51(4):536–541.
   PubMed Web of Science ®Google Scholar
• Mussolino C, Strouboulis J. Recent approaches for manipulating globin gene expression in treating hemoglobinopathies. Front Genome Ed. 2021;3:618111.
   PubMedGoogle Scholar
• Cai L, Bai H, Mahairaki V, et al. A universal approach to correct various HBB gene mutations in human stem cells for gene therapy of beta-thalassemia and sickle cell disease. Stem Cells Transl Med. 2018;7(1):87–97.
   PubMed Web of Science ®Google Scholar
• Frati G, Miccio A. Genome editing for β-hemoglobinopathies: advances and challenges. JCM. 2021;10(3):482.
   Google Scholar
• Pavani G, Fabiano A, Laurent M, et al. Correction of β-thalassemia by CRISPR/Cas9 editing of the β-globin locus in human hematopoietic stem cells. Blood Adv. 2021;5(5):1137–1153.
   PubMed Web of Science ®Google Scholar
• Suragani RNVS, Cadena SM, Cawley SM, et al. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20(4):408–414.
   PubMed Web of Science ®Google Scholar
• Arlet J-B, Ribeil J-A, Guillem F, et al. HSP70 sequestration by free β-globin promotes ineffective erythropoiesis in β-thalassaemia. Nature. 2014;514(7521):242–246.
   PubMed Web of Science ®Google Scholar
• Guillem F, Dussiot M, Colin E, et al. XPO1 regulates erythroid differentiation and is a new target for the treatment of β-thalassemia. Haematologica. 2020;105(9):2240–2249.
   PubMed Web of Science ®Google Scholar
• Madan U, Bhasin H, Dewan P, et al. Improving ineffective erythropoiesis in thalassemia: a hope on the horizon. Cureus. 2021;13(10):e18502.
   PubMed Web of Science ®Google Scholar
• Ramos P, Casu C, Gardenghi S, et al. Macrophages support pathological erythropoiesis in polycythemia vera and β-thalassemia. Nat Med. 2013;19(4):437–445.
   PubMed Web of Science ®Google Scholar
• Oikonomidou PR, Rivella S. What can we learn from ineffective erythropoiesis in thalassemia? Blood Rev. 2018;32(2):130–143.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Porter JB, Viprakasit V, et al. A paradigm shift on beta-thalassaemia treatment: how will we manage this old disease with new therapies? Blood Rev. 2018;32(4):300–311.
   PubMed Web of Science ®Google Scholar
• Taher AT, Cappellini MD. Luspatercept for β-thalassemia: beyond red blood cell transfusions. Expert Opin Biol Ther. 2021;21(11):1363–1371.
   PubMed Web of Science ®Google Scholar
• Ponka P, Koury MJ, Sheftel AD. Erythropoiesis, hemoglobin synthesis, and erythroid mitochondrial iron homeostasis. In: Ferreira GC, Kadish KM, Smith KM, Guilard A, editors. Handbook of Porphyrin Science: Erythropoiesis, Heme, Applications to Biomedicine. 1st ed. Toh Tuck Link (Singapore): World Scientific Publishers. 2013. p. 41–84.
   Google Scholar
• Cappellini MD, Porter J, Origa R, et al. A phase 2a, open-label, dose-finding study to determine the safety and tolerability of sotatercept (ACE-011) in adults with beta (β)-thalassemia: interim results. Blood. 2013;122(21):3448–3448.
   Web of Science ®Google Scholar
• Carrancio S, Markovics J, Wong P, et al. An activin receptor II A ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin. Br J Haematol. 2014;165(6):870–882.
   PubMed Web of Science ®Google Scholar
• Langdon JM, Barkataki S, Berger AE, et al. RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice. Am J Hematol. 2015;90(1):8–14.
   PubMed Web of Science ®Google Scholar
• Sherman ML, Borgstein NG, Mook L, et al. Multiple dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women. J Clin Pharmacol. 2013;53(11):1121–1130.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Harrison CN. Emerging treatments for classical myeloproliferative neoplasms. Blood. 2017;129(6):693–703.
   PubMed Web of Science ®Google Scholar
• Casu C, Presti VL, Oikonomidou PR, et al. Short-term administration of JAK2 inhibitors reduces splenomegaly in mouse models of β-thalassemia intermedia and major. Haematologica. 2018;103(2):e46–e49.
   PubMed Web of Science ®Google Scholar
• Libani IV, Guy EC, Melchiori L, et al. Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia. Blood. 2008;112(3):875–885.
   PubMed Web of Science ®Google Scholar
• Ben Salah N, Bou-Fakhredin R, Mellouli F, et al. Revisiting beta thalassemia intermedia: past, present, and future prospects. Hematology. 2017;22(10):607–616.
   PubMed Web of Science ®Google Scholar
• Taher AT, Karakas Z, Cassinerio E, et al. Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study. Blood. 2018;131(2):263–265.
   PubMed Web of Science ®Google Scholar
• Casu C, Chessa R, Liu A, et al. Minihepcidins improve ineffective erythropoiesis and splenomegaly in a new mouse model of adult β-thalassemia major. Haematologica. 2020;105(7):1835–1844.
   PubMed Web of Science ®Google Scholar
• Casu C, Oikonomidou PR, Chen H, et al. Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera. Blood. 2016;128(2):265–276.
   PubMed Web of Science ®Google Scholar
• Study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS TMPRSS6-LRx.: Onis Pharmaceuticals, Inc.; 2019. https://clinicaltrials.gov/ct2/show/NCT04059406? cond=NCT04059406&draw=2&rank=1
   Google Scholar
• Richard F, van Lier JJ, Roubert B, et al. Oral ferroportin inhibitor VIT 2763: first in human, phase 1 study in healthy volunteers. Am J Hematol. 2020;95(1):68–77.
   PubMed Web of Science ®Google Scholar
• Li H, Rybicki AC, Suzuka SM, et al. Transferrin therapy amelirates disease in β-thalassemic mice. Nat Med. 2010;16(2):177–182.
   PubMed Web of Science ®Google Scholar
• Gelderman MP, Baek JH, Yalamanoglu A, et al. Reversal of hemochormatosis by apotranferrin in non transfused Hbbth3/+ (heterozygous B1/B2 globin gene deletion) mice. Haematologica. 2015;100(5):611–622.
   PubMed Web of Science ®Google Scholar
• Tolosano E. Increasing serum tranferrin to reduce tissue iron overload due to ineffective erythropoiesis. Haematologica. 2015;100(5):565–566.
   PubMed Web of Science ®Google Scholar